1	TITLE: Development and use of a method based on the anti-N reactivity of longitudinal
2	samples to better estimate SARS-CoV-2 seroprevalence in a vaccinated population
3	
4	RUNNING HEAD: Novel method for SARS-CoV-2 prevalence
5	
6	AUTHORS: Renée Bazin <sup>1*</sup> , Samuel Rochette <sup>2</sup> , Josée Perreault <sup>1</sup> , Marie-Josée Fournier <sup>1</sup> ,
7	Yves Grégoire <sup>1</sup> , Amélie Boivin <sup>2</sup> , Antoine Lewin <sup>2,3</sup> , Marc Germain <sup>1</sup> , Christian Renaud <sup>2,4</sup>
8	<sup>1</sup> Affaires Médicales et Innovation, Héma-Québec, Québec, QC, Canada, GIV 4C3
9	<sup>2</sup> Affaires Médicales et Innovation, Héma-Québec, Montréal, QC, Canada, H4R 2W7
10	<sup>3</sup> Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke,
11	QC, Canada, J1K 2R1
12	<sup>4</sup> Département de microbiologie, CHU Sainte-Justine, Université de Montréal, Montréal,
13	QC, Canada, H3T 1C5
14	
15	*CORRESPONDING AUTHOR
16	Renée Bazin, PhD
17	Scientific Director, Medical Affairs and Innovation, Héma-Québec
18	1070 Ave des Sciences-de-la-Vie, Québec, QC Canada G1V 5C3
19	Phone: +1 418 780 4362 ext 3234; Fax: +1 418 780 2091
20	Email: renee.bazin@hema-quebec.qc.ca
21	
22	WORD COUNT: Abstract, 197; Main text, 1906.

## 23 FOOTNOTES

24

25	CONFLICT	<b>OF INTEREST:</b>	The authors have no	conflict of interest	to declare.
----	----------	---------------------	---------------------	----------------------	-------------

- 26
- 27 FUNDING: This work was supported by the Ministère de la Santé et des Services Sociaux
- 28 (MSSS) du Québec and the Public Health Agency of Canada (through the Reference Group
- 29 on the Surveillance of vaccines and the COVID-19 Immunity Task Force). The views
- 30 expressed here do not necessarily reflect those of the MSSS and Public Health Agency of
- 31 Canada.
- 32

## 33 CORRESPONDANCE AND REQUEST FOR REPRINTS:

- 34 Renée Bazin, PhD
- 35 Scientific Director, Medical Affairs and Innovation, Héma-Québec
- 36 1070 Ave des Sciences-de-la-Vie, Québec, QC Canada G1V 5C3
- 37 Phone: +1 418 780 4362 ext 3234; Fax: +1 418 780 2091
- 38 Email: renee.bazin@hema-quebec.qc.ca

## 39 ABSTRACT

Background: Emerging evidence suggests that COVID-19 vaccination decreases the
sensitivity of anti-nucleocapsid (N) serologies, making them less reliable to assess
recently-acquired infections. We therefore developed and tested a new approach based on
the ratio of the anti-N absorbance of longitudinal samples to overcome this limitation. *Methods:* Previously vaccinated repeat plasma donors provided at least one pre-infection
(reference) and one post-infection (test) sample. All samples were tested using an in-house
anti-N ELISA. Seropositivity was determined based on the ratio between the anti-N

47 absorbance of the test and reference samples. The ratio approach was tested in a real-world
48 setting during three cross-sectional serosurveys carried out among plasma donors in
49 Québec, Canada.

*Results:* Using a cut-off ratio of 1.5, the approach had a sensitivity of 95.2% among the 248 previously vaccinated and infected donors compared with 63.3% for the conventional approach. When tested in a real-world setting, the ratio-based approach yielded an adjusted seroprevalence of 27.4% (95% confidence interval [CI]=23.8%-30.9%) at the latest time point considered, compared to 15.1% (95% CI=12.2%-18.0%) for the conventional approach.

*Conclusions:* This article describes a new and highly-sensitive approach that captures a
significantly greater proportion of vaccinated individuals with a recent history of SARSCoV-2 infection.

59

60 KEYWORDS: COVID-19; Serosurvey; Anti-nucleocapsid; Vaccination; Absorbance ratio

## 61 **BACKGROUND**

Since the beginning of the SARS-CoV-2 pandemic, serosurveys have been key to public 62 health decision-making, but their conduct and interpretation have become more 63 challenging. Seroprevalence may no longer be viewed as an indicator of progression to a 64 65 putative state of herd immunity — a prospect that looks increasingly dim with the continual 66 emergence of immune-escape variants.[1,2] Early serosurveys assessed anti-spike (S) or anti-receptor binding domain (RBD) seropositivity in vaccine-naïve individuals, but this 67 68 approach cannot disentangle infection- from vaccine-induced seropositivity in vaccinated 69 individuals. Anti-nucleocapsid (N) seroprevalence was initially viewed as a solution to this 70 challenge but is more affected by seroreversion than anti-S or anti-RBD seroprevalence,[3– 71 12] thus leading to declining or stagnating seroprevalence estimates despite rising case 72 counts.[3,13,14] What is more, emerging evidence suggests that vaccination hinders the 73 sensitivity of conventional anti-N assays. In a study of 4000 fully vaccinated health care 74 workers, 23 experienced a breakthrough infection, but only six (26%) were seropositive for anti-N.[15] More recently, a study of COVE (i.e., mRNA-1273 vs. placebo to prevent 75 76 COVID-19) participants with a confirmed history of SARS-CoV-2 breakthrough infection 77 found that only 40.4% of vaccine recipients were seropositive for anti-N, as compared with 93.4% among placebo recipients.[16] Although preliminary, this evidence is worrisome as 78 79 it may invalidate conventional anti-N assays as a marker of SARS-CoV-2 infections, 80 leaving few alternatives to assess the progression of the pandemic.

The reduced rate of anti-N seroconversion among vaccinated individuals might be explained by reduced exposure to the N antigen following infection,[16] which may lead to anti-N levels that do not pass the seropositivity threshold of conventional anti-N assays.

We postulated that this limitation could be addressed by comparing the anti-N levels of samples collected at different time points, thus enabling the detection of meaningful signal increases in response to recently acquired infections. Based on this premise, we sought to develop and test an empirical approach to overcome the issue of vaccination in anti-N serosurveys.

#### 90 METHODS

#### 91 Donors

92 The approach was developed and tested based on longitudinally collected plasma samples 93 from regular plasma donors who consented to participate in a COVID-19-dedicated 94 biobank in Québec, Canada ("PlasCov"; see Supplementary Methods for details on the 95 biobank). The PlasCov biobank and the use of samples for the present study were approved 96 by the Héma-Québec Research Ethics Board. To develop the approach, plasma samples 97 from donors who met the following criteria were selected: (1) received  $\geq 1$  vaccine dose against SARS-CoV-2; (2) had a PCR-confirmed SARS-CoV-2 infection between 98 99 12/15/2021 and 03/20/2022 (i.e., during the Omicron wave); and (3) made  $\geq 2$  donations: 100 one before — but as close as possible — to 12/15/2021 (i.e., the reference sample collected 101 before the Omicron wave) and one between 01/02/2022 and 04/20/2022 after the confirmed infection (i.e., the test sample collected during the Omicron wave; see **Supplementary** 102 Methods for other inclusion criteria). To test the approach in a real-world setting, we 103 104 conducted three cross-sectional serosurveys in Québec (Canada) that included plasma 105 donors who made  $\geq 1$  donation in one of the following periods (all during the Omicron wave): 01/17/2022-01/18/2022, 02/14/2022-02/15/2022, and 03/16/2022-03/18/2022 (see 106 Supplementary Methods for other inclusion criteria). All of these donors were included 107 108 in the analysis conducted with the conventional approach, and only those with >1 reference 109 sample and  $\geq 1$  test sample were included in the analysis conducted with the new ratio-110 based approach (described further down).

111 Anti-N ELISA

All samples used to develop and test the ratio-based approach were analysed for anti-N 112 seropositivity using an in-house developed conventional anti-N ELISA. The assay was 113 similar to a previously described anti-RBD assay, [17] except that the recombinant N 114 antigen (Centre National en Électrochimie et en Technologies Environementales Inc., 115 Shawinigan, Canada) was used (0.25  $\mu$ g/ml) in lieu of the RBD antigen (2.5  $\mu$ g/ml). This 116 117 assay has a sensitivity of 98.5% and a specificity of 98.1% among unvaccinated and recently infected individuals using an absorbance cut-off value of 0.350 (see 118 119 Supplementary Methods for details).

#### 120 Ratio-based approach to determine anti-N seropositivity

121 The herein described ratio-based approach determines anti-N seropositivity based on the 122 ratio between the absorbances of the test and reference samples (anti-N ratio). The positivity cut-off for the anti-N ratio was selected based on the proportion of vaccinated 123 donors with a prior confirmed infection being captured (i.e., sensitivity). A baseline 124 threshold was applied to exclude samples with low absorbance values (i.e., falling in the 125 126 assay's background noise) and hence reduce false positives resulting from the technical 127 variability of the assay. Donors for whom the test sample had an absorbance value below this threshold were considered seronegative and no ratio was calculated. 128

## 129 Statistical analysis

Seroprevalence estimates were reported along with binomial proportion confidence
intervals (CI) after adjusting for age, sex, and regional distribution (based on 2011 census
data) for both cumulative and ratio-based approaches.

### 133 **RESULTS**

## 134 Development of the ratio-based approach

The approach was developed using 248 vaccinated donors with a PCR-confirmed infection during the Omicron wave (mean age: 40.6 years; females: 48.3%), including 246 (99.2%) who had received  $\geq$ 2 vaccine doses before their infection. The median interval between the PCR result and the collection of the test sample was 31 days (interquartile range: 19-46 days).

The target sensitivity of the ratio-based approach was 95%, as recommended by national
regulatory authorities.[18] A sensitivity > 95% was achieved with anti-N ratios of up to 1.5
and dropped abruptly at higher ratios (Figure 1). Therefore, a positivity cut-off of 1.5 was
selected.

To improve the specificity of the approach, we determined a limit of absorbance below which a test sample would not be included since low absorbance values are more variable and may inadvertently produce anti-N ratios  $\geq 1.5$  owing to the technical variability of the assay. Indeed, the coefficient of variation of 38 technical replicates of a negative control sample (pre-pandemic plasma pool) was 12.4% with a mean absorbance of 0.121. We therefore conservatively selected 0.100 for this lower limit of absorbance in test samples.

Applying the above-mentioned thresholds, the sensitivity of the ratio-based approach to identify new infections was estimated at 95.2% (236/248), whereas that of the conventional approach (based on the 0.350 seropositivity cut-off of the anti-N ELISA at the postinfection time point) was 63.3% (157/248).

The stability of the baseline anti-N signal in reference samples was assessed among seven 154 donors with an anti-N ratio >1.5 and three reference samples. For these donors, the anti-N 155 signal of the reference samples had a mean coefficient of variation (CV) of 10.7% (Figure 156 2), and all had an anti-N ratio  $\geq 1.5$  regardless of the reference sample considered. The 157 analysis of an additional 12 donors with 2 reference samples confirmed the low variability 158 159 of the baseline anti-N signal, with a mean CV of 8.4% (data not shown). False positives due to an unstable anti-N signal in reference samples thus appear to be infrequent, although 160 161 a larger sample would be needed to better estimate this rate.

#### 162 *Testing the ratio-based approach in a real-world setting*

163 The ratio-based approach was tested through a serosurvey that included 1618 plasma 164 donors (mean age=54.0 years; females=32.8%) who donated during the Omicron wave, of which 1519 (93.9%) were included in the analysis conducted with the ratio-based 165 approach. Using the ratio-based approach, the adjusted seroprevalence was 9.7% (95% 166 CI=7.1%-12.4%) for the period that covered the beginning of the Omicron wave up until 167 168 01/17/2022-01/18/2022, 20.3% (95% CI=16.8%-23.8%) for that up until 02/14/2022-169 02/15/2022, and 27.4% (95% CI=23.8%-30.9%) up until 03/16/2022-03/18/2022. Using the conventional approach, the adjusted seroprevalence was 8.3% (95% CI=6.0%-10.5%) 170 for samples collected between 01/17/2022 and 01/18/2022, 14.3% (95% CI=11.3%-17.4%) 171 172 between 02/14/2022 and 02/15/2022, and 15.1% (95% CI=12.2%-18.0%) between 173 03/16/2022 and 03/18/2022 (Figure 3).

## 174 **DISCUSSION**

This study presents a new approach (ratio-based approach) to assess the seroprevalence 175 176 during a period of interest. The approach relies on longitudinally collected samples and determines seropositivity based on the difference between the result of a test sample and 177 that of a reference sample collected earlier. In samples collected before and during the 178 Omicron wave of the SARS-CoV-2 pandemic, the approach had a sensitivity of 95.2% 179 among vaccinated individuals who had a breakthrough infection, which favorably 180 181 compares with the sensitivity of 63.3% obtained with the conventional approach. 182 Furthermore, at the latest time point considered in our analysis, this new approach estimated the adjusted anti-N seroprevalence at 27.4% during the Omicron wave, whereas 183 184 this estimate was only 15.4% with the conventional single-sample approach. The 185 conventional approach, as used in most (if not all) serosurveys, thus substantially 186 underestimated the seroprevalence of anti-N antibodies in vaccinated individuals, even 187 though it should theoretically reflect past infections since the onset of the pandemic, whereas the ratio-based approach measures seroprevalence only during a defined period of 188 189 interest (the Omicron wave in the present study).

In addition to providing a high sensitivity, a cut-off of 1.5 for the anti-N ratio seemed adequate to reduce false positives that may arise due to the technical variability of the ELISA. The CV of negative controls (n=38 technical replicates) was 12.4%, and that of positive controls (n=38 technical replicates) was 11.3%, suggesting a cut-off lower than  $\sim$ 1.3 (i.e., [100%+12%]/[100%-12%]) would be inadequate owing to the assay's technical variability. The selected cut-off thus probably represents a good compromise between sensitivity and technical false positives.

The sensitivity of the conventional approach (63.3%) was higher than that reported in 197 previous studies for vaccinated individuals (26.0%-40.4%).[15,16] Besides differences 198 199 among assays, this discrepancy may be explained by the fact that the Omicron variant (for which vaccine efficacy is lower) was dominant during our study, whereas earlier variants 200 (for which vaccine efficacy is higher) were dominant in previous studies.[19–22] As a 201 202 result, individuals included in our study may have been exposed to higher viral loads than 203 those included in previous studies, thereby increasing the likelihood of anti-N 204 seroconversion.

205 The ratio-based approach estimated the adjusted anti-N seroprevalence at 27.4% during a 206 period that covered the Omicron wave up until mid-March 2022. This figure is consistent 207 with a recent modeling study, which estimated at 32% the proportion of Montreal residents 208 who contracted SARS-CoV-2 between 12/01/2021 and 02/21/2022.[23] By contrast, the 209 conventional approach estimated the adjusted anti-N seroprevalence at 15.1% in mid-210 March 2022. Together with the sensitivity data described above, these results demonstrate 211 the extent to which the ratio-based approach captures a larger share of infections than the 212 conventional approach.

This study has a few limitations. To begin, the true specificity of the ratio-based approach could not be assessed because of the unavailability of longitudinal samples from individuals ascertained not to have a history of SARS-CoV-2 infection (e.g., pre-pandemic longitudinal samples). However, the approach accounts for technical false positives by specifying a lower limit of absorbance below which test samples cannot be considered positive. In addition, the ratio-based approach requires access to at least 2 relatively recent samples per individual, which limits the pool of individuals that can be included in the

analyses. Furthermore, the plasma donors who participated in PlasCov may not be
representative of the general population. These individuals are generally healthier[24] and
more of them are vaccinated against COVID-19 compared with the general population.
Lastly, the legal age for plasma donation is 18 or older, and so children were not included
in this study.

225

## 226 CONCLUSION

This article describes a new and highly-sensitive approach (ratio-based approach) that successfully addresses the issue of vaccination in serosurveys. Relative to the conventional approach, the ratio-based approach captured a significantly greater proportion of vaccinated individuals with a recent history of SARS-CoV-2 infection (i.e., 95.2% vs. 63.3%). When tested in a real-world setting, this new approach also yielded a significantly higher anti-N seroprevalence than the conventional approach (i.e., 27.4% vs. 15.4%).

233

# 235 ACKNOWLEDMENTS

- 236 The authors thank all the plasma donors who participate in the PlasCov biobank and the
- 237 Héma-Québec personnel involved in sample collection and recovery from the biobank's
- 238 inventory.

## 239 **REFERENCES**

240	1.	Aschwanden C. Five reasons why COVID herd immunity is probably impossible.
241		Nature <b>2021</b> ; 591:520–522.
242	2.	Barber RM, Sorensen RJ, Pigott DM, et al. Estimating global, regional, and national
243		daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a
244		statistical analysis. The Lancet 2022; 399:2351-2380.
245	3.	Bolotin S, Tran V, Osman S, et al. SARS-CoV-2 seroprevalence survey estimates
246		are affected by anti-nucleocapsid antibody decline. J Infect Dis 2021; 223:1334-
247		1338.
248	4.	Whitcombe AL, McGregor R, Craigie A, et al. Comprehensive analysis of SARS-
249		CoV-2 antibody dynamics in New Zealand. Clin Transl Immunol 2021; 10:e1261.
250	5.	Carreño JM, Mendu DR, Simon V, et al. Longitudinal analysis of severe acute
251		respiratory syndrome coronavirus 2 seroprevalence using multiple serology
252		platforms. Iscience 2021; 24:102937.
253	6.	Gallais F, Gantner P, Bruel T, et al. Evolution of antibody responses up to 13
254		months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine 2021;
255		71:103561.
256	7.	Nunhofer V, Weidner L, Hoeggerl AD, et al. Persistence of Naturally Acquired and
257		Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection.
258		Viruses <b>2022</b> ; 14:637.

259	8.	Fedele G, Stefanelli P, Bella A, et al. Anti-SARS-CoV-2 antibodies persistence after
260		natural infection: a repeated serosurvey in Northern Italy: COVID-19 IgG longevity
261		and neutralization. Ann Ist Super Sanita 2021; 57:265–271.
262	9.	Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 spike versus
263		nucleoprotein antibody responses impact the estimates of infections in population-
264		based seroprevalence studies. J Virol 2021; 95:e01828-20.
265	10.	Grandjean L, Saso A, Torres Ortiz A, et al. Long-Term Persistence of Spike Protein
266		Antibody and Predictive Modeling of Antibody Dynamics After Infection With
267		Severe Acute Respiratory Syndrome Coronavirus 2. Clin Infect Dis 2021; 74:1220-
268		1229.
269	11.	Pilmis B, Elkaibi I, Ponfilly GP de, et al. Evolution of anti-SARS-CoV-2 immune
270		response in a cohort of French healthcare workers followed for 7 months. Infect Dis
271		Now <b>2022</b> ; 52:68-74.
272	12.	Lee CC, Segaloff HE, Cole D, et al. A cohort study measuring SARS-CoV-2
273		seroconversion and serial viral testing in university students. BMC Infect Dis 2022;
274		22:1–11.
275	13.	Jones JM, Stone M, Sulaeman H, et al. Estimated US infection-and vaccine-induced
276		SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021.
277		JAMA <b>2021</b> ; 326:1400–1409.
278	14.	Siller A, Seekircher L, Wachter GA, et al. Seroprevalence, Waning and Correlates
279		of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of

280		35,193 Blood Donors Conducted between June 2020 and September 2021. Viruses
281		<b>2022</b> ; 14:568.
282	15.	Allen N, Brady M, Martin AIC, et al. Serological markers of SARS-CoV-2
283		infection; anti-nucleocapsid antibody positivity may not be the ideal marker of
284		natural infection in vaccinated individuals. J Infect 2021; 83:e9-e10.
285	16.	Follmann D, Janes HE, Buhule OD, et al. Anti-nucleocapsid antibodies after SARS-
286		CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-
287		1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med. Jul 5, 2022.
288		Available from: https://doi: 10.7326/M22-1300.
289	17.	Perreault J, Tremblay T, Fournier M-J, et al. Waning of SARS-CoV-2 RBD
290		antibodies in longitudinal convalescent plasma samples within 4 months after
291		symptom onset. Blood <b>2020</b> ; 136:2588-2591.
292	18.	Government of Canada. COVID-19 serological testing devices: Notice on
293		sensitivity and specificity values [Internet]. [cited 2022 Jun 17]. Available from:
294		https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-
295		industry/medical-devices/testing/serological/notice-sensitivity-specificity-
296		values.html
297	19.	Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters
298		against SARS-CoV-2 omicron infection in Qatar. N Engl J Med 2022; 386:1804-
299		1816.

300	20.	Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of
301		mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2
302		Omicron and Delta variants. Jama 2022; 327:639–651.
303	21.	Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273
304		SARS-CoV-2 vaccine. N Engl J Med <b>2020</b> ; 384:403-416.
305	22.	Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2
306		mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603-2615.
307	23.	Brisson, M, Hardy, M, Gingras, G, Drolet, M, Laprise, JF. Modélisation de l'impact
308		potentiel des assouplissements des mesures sanitaires sur l'évolution de la COVID-
309		19 dans le Grand Montréal [Internet]. [cited 2022 Apr 13]. Available from:
310		https://marc-brisson.net/covid19-response/Modelisation-evolution-COVID-19-au-
311		Quebec_Rapport19_2-mars-2022.pdf
312	24.	Golding J, Northstone K, Miller LL, Davey Smith G, Pembrey M. Differences
313		between blood donors and a population sample: implications for case-control

studies. Int J Epidemiol 2013; 42:1145–1156.

314

## **FIGURE LEGENDS**

**Figure 1. Sensitivity of detection of seropositive individuals captured using various anti-N ratio.** The ratio of the anti-N signal between the test and reference samples was calculated. The sensitivity of detection obtained for ratios between 0.5 and 2.8 is shown. Sensitivity below the target value of 95% is indicated by the grey area.

Figure 2: Stability of the anti-N signal in reference samples. Results of the anti-N ELISA for 7 individuals with three reference (pre-infection) samples. Day 0 represents the collection of the first reference sample; the interval (in days) between the collection of the first sample and the other samples is shown on the x axis. The first 3 dots on each panel show the results of reference samples and the last dot shows the result of the post-infection sample. The coefficient of variation of the results for the 3 reference samples is indicated on each graph.

**Figure 3.** Adjusted seroprevalence obtained with the conventional and ratio-based approaches. The adjusted seroprevalence (age, sex, and regional distribution of the participants) was calculated using the ratio-based approach with samples covering 3 time intervals: A-C) since date of reference sample collection up to A) 17-18 January 2022, B) 14-15 February 2022 or C) 16-18 March 2022. The adjusted seroprevalence was also calculated using the conventional approach with samples collected at 3 different time points: A) 17-18 January 2022; B) 14-15 February 2022; C) 16-18 March 2022. The shaded areas around the lines represent the 95% confidence intervals of the seroprevalence estimates.

# FIGURE 1





## FIGURE 2

## FIGURE 3

